Study shows benefits and risks from GLP-1RAs

21 January 2025

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are increasingly being used to treat diabetes and obesity.

This study, published Monday in Nature Medicine, used US Department of Veterans Affairs databases to build a cohort of people with diabetes who started treatment with GLP-1Ras and compared them to those who began taking sulfonylureas, dipeptidyl peptidase 4 (DPP4) inhibitors or sodium−glucose cotransporter-2 (SGLT2) inhibitors, a control group composed of an equal proportion of people initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors, and a control group who continued with non-GLP-1RA antihyperglycemics (usual care). -

Leading on-market GLP-1Ras include semaglutide - Novo Nordisk’s (NOVN: VX) drug marketed as Wegovy and Ozempic, and Eli Lilly’s (NYSE: LLY) tirzepatide, which is branded as Mounjaro and Zepbound.   

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical